Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
August 22, 2019 12:24 ET
|
Arch Biopartners
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....
Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing
March 09, 2018 08:00 ET
|
Arch Biopartners
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the...
Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio
February 27, 2018 07:30 ET
|
Arch Biopartners
TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced CSBio of Menlo Park,...
C3 Jian Obtains FDA Acceptance of Investigational New Drug Application
May 24, 2012 12:06 ET
|
C3 Jian, Inc.
LOS ANGELES, May 24, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that its Investigational New Drug Application (IND) for...